Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.
Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, Kiessling R, Blankenstein T, Abken H, Charo J. Kruschinski A, et al. Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17481-6. doi: 10.1073/pnas.0804788105. Epub 2008 Nov 5. Proc Natl Acad Sci U S A. 2008. PMID: 18987320 Free PMC article.
Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition.
Weisberg EL, Sattler M, Azab AK, Eulberg D, Kruschinski A, Manley PW, Stone R, Griffin JD. Weisberg EL, et al. Among authors: kruschinski a. Oncotarget. 2017 Nov 6;8(66):109973-109984. doi: 10.18632/oncotarget.22409. eCollection 2017 Dec 15. Oncotarget. 2017. PMID: 29299123 Free PMC article.
Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12.
Vater A, Sahlmann J, Kröger N, Zöllner S, Lioznov M, Maasch C, Buchner K, Vossmeyer D, Schwoebel F, Purschke WG, Vonhoff S, Kruschinski A, Hübel K, Humphrey M, Klussmann S, Fliegert F. Vater A, et al. Among authors: kruschinski a. Clin Pharmacol Ther. 2013 Jul;94(1):150-7. doi: 10.1038/clpt.2013.58. Epub 2013 Mar 19. Clin Pharmacol Ther. 2013. PMID: 23588307
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.
Ganghammer S, Hutterer E, Hinterseer E, Brachtl G, Asslaber D, Krenn PW, Girbl T, Berghammer P, Geisberger R, Egle A, Zucchetto A, Kruschinski A, Gattei V, Chigaev A, Greil R, Hartmann TN. Ganghammer S, et al. Among authors: kruschinski a. Oncotarget. 2015 May 20;6(14):12048-60. doi: 10.18632/oncotarget.3660. Oncotarget. 2015. PMID: 25895128 Free PMC article.
SDF-1 inhibition targets the bone marrow niche for cancer therapy.
Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, Zboralski D, Zöllner S, Vonhoff S, Mishima Y, Maiso P, Reagan MR, Lonardi S, Ungari M, Facchetti F, Eulberg D, Kruschinski A, Vater A, Rossi G, Klussmann S, Ghobrial IM. Roccaro AM, et al. Among authors: kruschinski a. Cell Rep. 2014 Oct 9;9(1):118-128. doi: 10.1016/j.celrep.2014.08.042. Epub 2014 Sep 25. Cell Rep. 2014. PMID: 25263552 Free PMC article.
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.
Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Leitgeb C, Foa R, Greil R, Yakoub-Agha I, Zboralski D, Vauléon S, Dümmler T, Beyer D, Kruschinski A, Riecke K, Baumann M, Engelhardt M. Ludwig H, et al. Among authors: kruschinski a. Leukemia. 2017 Apr;31(4):997-1000. doi: 10.1038/leu.2017.5. Epub 2017 Jan 11. Leukemia. 2017. PMID: 28074071 Free PMC article. Clinical Trial. No abstract available.
11 results